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Background: Interstitial lung disease (ILD) is frequently associated with collagen diseases. The prognosis of
acute-onset diffuse ILD (AoDILD) occurring in collagen disease patients is very poor. Here, we investigated
serum biomarker profiles of AoDILD to find markers predicting outcome in patients with collagen diseases.
Methods: A solid-phase antibody array was used for screening 274 biomarkers in pooled sera from collagen
disease patients in the AoDILD state and in the stable state. Biomarkers in individual sera were detected
without pooling by bead-based immunoassay.
Results: The serum levels of matrix metalloproteinase (MMP)-1, tissue inhibitor of metalloproteinase (TIMP)-1,
osteopontin, interleukin (IL)-2 receptor α (IL-2Rα), and IL-1 receptor antagonist were significantly increased in
AoDILD, but TIMP-2, MMP-3, and eotaxin 2 levels were decreased. The MMP-3 to MMP-1 ratio was reduced in
AoDILD state. This tendency was also observed in RA patients with AoDILD. Moreover, serum IL-6 level was
significantly increased in the AoDILD state in patients with acute exacerbation of ILD (AE-ILD). Serum TIMP-1
and IL-2Rα levels were significantly increased in the AoDILD state in patients with drug-induced ILD (DI-ILD),
whereas TIMP-2, MMP-3, and eotaxin 2 levels were decreased. The MMP-3 to MMP-1 ratio was reduced in
AoDILD state in patients with DI-ILD. The serum TIMP-3, MMP-9, osteopontin, IL-2Rα, MMP-1, and MMP-8 levels
were significantly increased in the AoDILD state in patients who subsequently died, whereas TIMP-2 and MMP-3
levels were decreased in those who survived. The MMP-3 to MMP-1 ratio was reduced in AoDILD state in
patients who died, but not in those who survived.
Conclusions: Serum biomarker profiles could represent prognosis markers for AoDILD in collagen diseases.
Keywords: Collagen disease, Biomarker, Cytokine, Interstitial lung diseaseBackground
Interstitial lung disease (ILD) is characterized by intersti-
tial inflammation of the lung and is frequently associated
with collagen diseases, when it is designated collagen
vascular disease-associated ILD (CVD-ILD). CVD-ILD is
one of the major manifestations of collagen disease that
influence the prognosis [1,2]. Acute-onset diffuse ILD
(AoDILD) occurs in patients with collagen disease with* Correspondence: h-furukawa@sagamihara-hosp.gr.jp
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reproduction in any medium, provided the oror without underlying CVD-ILD [3]. AoDILD includes
acute exacerbation of ILD (AE-ILD), drug-induced ILD
(DI-ILD), and Pneumocystis pneumonia. The prognosis
of AoDILD is quite poor. AE-ILD is due to collagen dis-
eases per se and characterized by pathological findings of
diffuse alveolar damage overlapping with chronic fibrotic
lung. DI-ILD occurs frequently in rheumatoid arthritis
(RA) patients treated with methotrexate. Pneumocystis
pneumonia is defined by the presence of P. jirovecii
organisms in the respiratory tract. However, the classifi-
cation of AoDILD is not established.
The roles of several cytokines, chemokines, matrix
metalloproteinases (MMPs) and tissue inhibitors ofs is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Biomarker levels in individual serum without
pooling from collagen disease patients in the stable and
AoDILD states
Biomarker (pg/ml) Stable AoDILD P
TIMP-1 207843 (57972) 285600 (98476) 0.015
TIMP-2 121481 (22995) 101922 (18568) 0.006
TIMP-3 15662 (11925) 15653 (7974) 0.196
TIMP-4 2908 (941) 2874 (837) 0.906
MMP-3 854165 (668239) 499442 (312919) 0.010
MMP-9 2615399 (1577133) 2837226 (1619793) 0.563
TGF-β1 57391 (12908) 52821 (16415) 0.101
TGF-β2 2475 (889) 2201 (997) 0.101
TGF-β3 0 (0) 0 (0) 1.000
Leptin 6424 (6663) 6275 (8249) 0.670
Osteopontin 14603 (12657) 30216 (33636) 0.012
Insulin 633 (475) 589 (330) 0.961
EGF 131 (124) 130 (189) 0.355
Eotaxin2 4497 (3166) 4223 (5065) 0.018
Eotaxin3 44 (71) 37 (52) 0.625
IL-17 F 125 (340) 168 (519) 0.761
IL-1α 61 (248) 137 (607) 1.000
IL-1RA 156 (330) 401 (490) 0.049
IL-2 41 (121) 77 (246) 0.427
IL-2Rα 3623 (2134) 7469 (6483) 0.001
IL-6 103 (234) 363 (794) 0.035
Fas 2237 (9967) 3450 (13337) 0.715
FasL 68 (63) 74 (74) 0.763
TNFα 841 (1953) 1052 (2676) 0.821
MMP-1 69662 (86194) 75510 (58379) 0.016
MMP-12 4992 (14919) 7406 (23641) 0.500
MMP-7 5874 (5153) 7871 (11084) 0.627
MMP-13 37860 (74534) 52019 (111830) 0.754
MMP-8 25817 (17712) 48700 (54791) 0.144
LIF 57 (150) 121 (353) 0.441
MIF 17352 (34236) 23178 (29813) 0.136
MMP-3/MMP-1 22.04 (18.56) 15.00 (19.61) 0.0208
AoDILD: acute-onset diffuse interstitial lung disease. Average values of each
group are shown. Standard deviations are shown in parenthesis. Differences
were tested by Wilcoxon signed-rank test.
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pulmonary fibrosis (IPF) and in acute respiratory distress
syndrome (ARDS) [4-6]. Few studies have focused on
AoDILD in collagen diseases. Therefore, we investigated
the serum biomarker profile of AoDILD in collagen
diseases in order to shed light on pathogenesis and




Twenty-five patients with collagen diseases (mean age ±
standard deviation (SD): 65.9 ± 10.8 years; 11 men) were
admitted to Sagamihara Hospital between 2001 and 2010,
because of AoDILD requiring corticosteroid pulse therapy.
AoDILD was defined as acute onset and progression within
a month, the presence of clinical symptoms (fever, dry
cough, or dyspnea), hypoxia, and computed tomography
findings of ILD [3]. Patients with evidence of apparent bac-
terial infection or heart disease were excluded. These 25
collagen disease patients with AoDILD include 9 AE-ILD,
16 DI-ILD, and no Pneumocystis pneumonia. In this study,
AoDILD was classified to AE-ILD, DI-ILD, and Pneumocys-
tis pneumonia as following: Pneumocystis pneumonia was
defined by the presence of P. jirovecii organisms detected
by polymerase chain reaction for P. jirovecii or Grocott
stain from bronchoalveolar lavage fluids or sputa of
patients, DI-ILD was defined as AoDILD with treatment of
DI-ILD causing drugs (disease-modifying anti-rheumatic
drugs or immunosuppressants excluding corticosteroid) at
onset after the exclusion of Pneumocystis pneumonia, AE-
ILD was defined as AoDILD without treatment of DI-ILD
causing drugs at onset, but with underlying CVD-ILD, after
the exclusion of Pneumocystis pneumonia and DI-ILD.
These 16 patients with DI-ILD were treated at onset with
methotrexate (n = 10), gold sodium thiomalate (n = 1),
tacrolimus (n = 2), cyclophosphamide (n = 1), or etanercept
(n = 2). Sera were collected on admission, and in the stable
state, at least three months before admission. They were
classified according to the American College of Rheumatol-
ogy criteria for RA [7], systemic sclerosis (SSc) [8], and
Bohan’s criteria for polymyositis/dermatomyositis (PM/
DM) [9]. Diagnoses of the patients included 20 RA, 2 SSc,
and 3 PM/DM. These 25 collagen disease patients with
AoDILD include 11 patients who died and 14 who sur-
vived, during the course of AoDILD. The major cause of
death of these 11 patients would be respiratory failure due
to AoDILD, though the complication of infection due to re-
petitive corticosteroid pulse therapy could not be com-
pletely excluded. This study was reviewed and approved by
Sagamihara Hospital Research Ethics Committee. Written
informed consent was obtained from all study participants
except those already deceased before starting this study.
The serum samples collected before this study wereanonymized in a fashion preventing any link with the
patients’ identification and their analysis approved on that
condition by Sagamihara Hospital Research Ethics Com-
mittee. This study was conducted in accordance with the
principles expressed in the Declaration of Helsinki.
Biomarker immunoassay
RayBio human cytokine antibody array (RayBiotech,
Norcross, GA) was used for detection of 274 biomarkers
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ding to the manufacturer’s protocol. The Bio-Plex sus-
pension array system (Bio-rad, Hercules, CA) was
used for detection of biomarkers in individual sera
from patients in the two different states, without
pooling. Fluorokine MAP multiplex kits (R&D
Systems, Minneapolis, MN) were used for detection of
TIMP-1, TIMP-2, TIMP-3, and TIMP-4. Milliplex
map kits (Millipore, Billerica, MA) were used for
detection of transforming growth factor (TGF)-β1,
TGF-β2, TGF-β3, leptin, osteopontin, and insulin.
Procarta cytokine plex kits (Affymetrix, Santa Clara,
CA) were used for detection of MMP-3, MMP-9,
epidermal growth factor (EGF), (IL)-17F, IL-1α,
IL-1 receptor antagonist (IL-1RA), IL-2, IL-2 receptor α
(IL-2Rα), IL-6, Fas, Fas ligand (FasL), tumor necrosis
factor (TNF)α, MMP-1, MMP-12, MMP-7, MMP-13,
MMP-8, leukaemia inhibitory factor (LIF), and migration
inhibitory factor (MIF).Statistical analysis
Differences in patient characteristics were analyzed by
Mann-Whitney U test or Fisher’s exact test using
2×2 contingency tables. Wilcoxon signed-rank test or
Mann-Whitney U test was performed in the comparison of
laboratory findings and biomarker assay results. It was
defined statistical significance as P < 0.05.Figure 1 Biomarker profile of acute-onset diffuse interstitial lung dise
collagen disease and rheumatoid arthritis (RA) patients were indicated in A
exacerbation of ILD (AE-ILD) and drug-induced interstitial lung disease (DI-I
in AoDILD state of patients who subsequently died and those who surviveResults
Characteristics of collagen disease patients with AoDILD
In 84% (n = 21) of the patients with AoDILD, underlying
CVD-ILD had been detected prior to the onset of
AoDILD. Mortality of patients during the AoDILD state
was 44% (n = 11). Lactate dehydrogenase, blood urea
nitrogen, KL-6, and surfactant protein-D (SP-D) were
more increased in AoDILD than in the stable state
(Additional file 1: Table S1). Albumin was decreased in
the AoDILD state compared to these patients in the
stable state.Biomarker immunoassay
Sera were pooled from 25 collagen disease patients in each
state, i.e. stable and AoDILD. We assessed the presence of
274 biomarkers in these two pooled sera. Eighteen of them
were found to be present at less than 0.67 times the level
in the pooled sera at AoDILD compared to the stable state
(Additional file 2: Table S2). Five biomarkers were present
in AoDILD sera at levels more than 1.5 times the stable
state. In addition to these 23 up-regulated or down-
regulated biomarkers, several biomarkers were included
from the results of previous studies on IPF or ARDS for
candidates of further analysis [4,6,10-18]. Thirty one
biomarkers were selected based on the availability of
bead-based immunoassay for more detailed analysis. Up-
regulated soluble TNF receptor II in this pooled assayase (AoDILD). Increased and decreased biomarkers in AoDILD state of
. Increased and decreased biomarkers in AoDILD state of acute
LD) patients were indicated in B. Increased and decreased biomarkers
d were indicated in C.
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uble TNF receptor II-Fc fusion protein, etanercept. Be-
cause administration of antibody or recombinant cytokine
receptors skews the cytokine profile [19], sera from the
2 RA patients treated with etanercept were excluded
from the following individual biomarker analysis. The
serum biomarker levels of the 23 collagen disease
patients in the stable state and at AoDILD without
pooling are shown in Table 1 and Additional file 3:
Figure S1. Serum TIMP-1, osteopontin, IL-1RA, IL-
2Rα, IL-6, and MMP-1 levels were significantly increased
in the AoDILD state (Table 1, Figure 1A), whereas TIMP-
2, MMP-3, and eotaxin 2 levels were decreased. The ratio
of MMP-3 to MMP-1 was reduced in the AoDILD state in
these patients.Table 2 Laboratory findings and serum biomarker levels of th
RA patients (n =
Stable
White Blood Cell count(X1000/ml) 10.5 (3.8)





Aspartate Aminotransferase(IU/l) 32.6 (39.8)
Alanine Aminotransferase(IU/l) 28.0 (36.3)
Lactate Dehydrogenase(IU/l) 224.7 (39.1)
Alkaline Phosphatase(IU/l) 275.4 (129.1)
γ-glutamyltransferase(IU/l) 33.5 (25.4)
Creatinine(mg/dl) 0.6 (0.1)
Blood Urea Nitrogen(mg/dl) 14.2 (2.8)
C-reactive protein(mg/dl) 3.6 (3.6)
KL-6(IU/ml) 447.9 (244.3)












RA: rheumatoid arthritis, AoDILD: Acute-onset diffuse interstitial lung disease. Avera
parenthesis. Differences were tested by Wilcoxon signed-rank test.Serum biomarker profile of the RA patients with AoDILD
We next explored biomarkers associated with AoDILD
in the patients with RA. Characteristics of the RA
patients (n = 18) are compared with that of collagen dis-
ease patients (n = 23) in Additional file 4: Table S3. The
laboratory findings of the RA patients in the stable state
and in the AoDILD state are shown in Table 2. KL-6,
SP-D, and lactate dehydrogenase were increased in
AoDILD of patients with RA. Albumin was decreased in
AoDILD of patients with RA.
While the serum TIMP-1, osteopontin, and IL-
2Rα levels were increased in patients with RA in the
AoDILD state (Table 2, Figure 1A), TIMP-2, MMP-3,
and eotaxin 2 were decreased. The ratio of MMP-3 to






























ge values of each group are shown. Standard deviations are shown in
Table 3 Laboratory findings and serum biomarker levels of collagen disease patients with AE-ILD or DI-ILD in stable
and AoDILD states
AE-ILD (n = 9) DI-ILD (n = 14)
Stable AoDILD P Stable AoDILD P
White Blood Cell count (X1000/ml) 10.9 (2.7) 11.8 (2.6) 0.2135 10.3 (4.0) 12.1 (3.8) 0.2604
Red Blood Cell count (X106/ml) 4.2 (0.9) 4.4 (0.7) 0.9528 4.2 (0.5) 4.1 (0.6) 0.5536
Hemoglobin (g/dl) 13.4 (1.2) 12.7 (2.5) 0.2936 12.6 (2.3) 12.2 (1.9) 0.5147
Hematocrit (%) 42.1 (3.1) 38.9 (6.4) 0.0152 38.9 (6.4) 36.9 (5.9) 0.9528
Platelet (X1000/ml) 280.3 (58.0) 299.5 (110.0) 0.3139 318.2 (139.3) 293.5 (118.8) 0.8590
Albumin (g/dl) 4.1 (0.3) 3.6 (0.7) 0.0077 3.9 (0.4) 3.2 (0.6) 0.0687
Aspartate Aminotransferase (IU/l) 41.2 (47.9) 44.4 (32.4) 0.6784 23.2 (4.6) 31.8 (13.6) 0.1282
Alanine Aminotransferase (IU/l) 36.6 (43.2) 39.0 (36.2) 0.4838 19.7 (6.8) 18.0 (6.0) 0.6784
Lactate Dehydrogenase (IU/l) 250.7 (45.3) 311.6 (86.2) 0.1386 215.2 (23.8) 383.6 (158.3) 0.0209
Alkaline Phosphatase (IU/l) 278.1 (141.2) 239.3 (97.9) 0.7794 243.8 (89.5) 261.8 (90.2) 0.9528
γ-glutamyltransferase (IU/l) 52.2 (44.4) 179.5 (392.2) 0.1551 26.3 (18.0) 31.1 (14.9) 0.4990
Creatinine (mg/dl) 0.7 (0.1) 0.7 (0.1) 0.8127 0.6 (0.1) 0.7 (0.2) 0.8127
Blood Urea Nitrogen (mg/dl) 13.9 (2.3) 17.1 (6.2) 0.1097 14.4 (3.1) 16.8 (3.5) 0.4008
C-reactive protein (mg/dl) 2.1 (2.3) 6.4 (10.1) 0.1097 3.9 (4.1) 11.2 (7.7) 0.2135
KL-6 (U/ml) 2078.1 (2525.4) 2105.8 (2495.5) 0.0280 431.0 (256.6) 799.7 (425.9) 0.0208
Surfactant Protein-D (ng/ml) 160.7 (126.5) 194.7 (123.2) 0.1763 76.4 (53.5) 170.5 (163.6) 0.0619
TIMP-1 (pg/ml) 192899 (54474) 245030 (93165) 0.3105 218303 (58054) 313999 (91931) 0.0166
TIMP-2 (pg/ml) 123534 (24219) 100422 (12693) 0.1763 120044 (21985) 102973 (21694) 0.0125
TIMP-3 (pg/ml) 16813 (5411) 18791 (9923) 0.7353 14857 (14822) 13457 (5240) 0.1097
MMP-3 (pg/ml) 587882 (245290) 628244 (328962) 0.5940 1025348 (787427) 416640 (271619) 0.0019
MMP-9 (pg/ml) 2852316 (1698909) 2800269 (1205613) 0.5940 2463095 (1473636) 2860985 (1837002) 0.5509
Osteopontin (pg/ml) 12464 (10678) 28442 (35397) 0.0663 15979 (13604) 31356 (32402) 0.0736
Eotaxin2 (pg/ml) 3953 (2312) 5311 (5724) 0.3139 4846 (3566) 3523 (4453) 0.0258
IL-1RA (pg/ml) 94 (111) 417 (653) 0.0796 196 (409) 390 (346) 0.2209
IL-2Rα (pg/ml) 2611 (1669) 3689 (2047) 0.0506 4274 (2147) 9899 (7159) 0.0076
IL-6 (pg/ml) 37 (47) 238 (422) 0.0209 145 (290) 444 (952) 0.2455
MMP-1 (pg/ml) 26532 (18626) 44551 (43273) 0.1097 97389 (100090) 95411 (58164) 0.0962
MMP-8 (pg/ml) 24640 (18134) 49581 (74715) 0.3743 26573 (17394) 48134 (36641) 0.1401
MMP-3/MMP-1 29.78 (16.71) 29.11 (24.88) 0.7671 17.07 (17.98) 5.92 (4.81) 0.0043
AoDILD: Acute-onset diffuse interstitial lung disease, AE-ILD: acute exacerbation of interstitial lung disease, DI-ILD: drug-induced interstitial lung disease. Average
values of each group are shown. Standard deviations are shown in parenthesis. Differences were tested by Wilcoxon signed-rank test.
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collagen disease patients with AoDILD.
Serum biomarker profile of the patients with AE-ILD or
DI-ILD
We also explored biomarkers associated with AoDILD
in the patients with AE-ILD or DI-ILD. Characteristics
of the AE-ILD (n = 9) and DI-ILD patients (n = 14) are
shown in Additional file 5: Table S4. The laboratory
findings of the patients with AE-ILD or DI-ILD in the
stable state and in the AoDILD state are shown in
Table 3. KL-6 was increased in AoDILD of patients with
AE-ILD. Albumin and hematocrit were decreased inAoDILD of patients with AE-ILD. KL-6 and lactate
dehydrogenase were increased in AoDILD of patients
with DI-ILD.
The serum IL-6 level was significantly increased in
patients with AE-ILD in the AoDILD state (Table 3,
Figure 1B). While the serum TIMP-1 and IL-2Rα levels
were significantly increased in patients with DI-ILD in the
AoDILD state (Table 3, Figure 1B), TIMP-2, MMP-3, and
eotaxin 2 were decreased. The ratio of MMP-3 to MMP-1
was also reduced in the AoDILD state in these patients.
These skewed biomarker profiles suggest differences in the
pathogenesis of AoDILD in patients with AE-ILD or
DI-ILD.
Table 4 Laboratory findings and serum biomarker levels of collagen disease patients with different clinical outcome in
stable and AoDILD states
Died (n = 9) Survived (n = 14)
Stable AoDILD P Stable AoDILD P
White Blood Cell count(X1000/ml) 8.5 (1.7) 10.4 (1.8) 0.138 11.4 (3.6) 13.0 (3.7) 0.279
Red Blood Cell count(X106/ml) 4.3 (0.3) 3.9 (0.7) 0.043 4.1 (0.8) 4.4 (0.6) 0.069
Hemoglobin(g/dl) 13.7 (1.2) 11.7 (2.7) 0.043 12.7 (2.0) 12.9 (1.7) 0.108
Hematocrit(%) 41.5 (3.5) 35.6 (6.7) 0.043 40.1 (5.8) 39.2 (5.4) 0.917
Platelet(X1000/ml) 266.0 (62.5) 310.1 (131.2) 0.281 312.1 (119.0) 287.1 (102.4) 0.972
Albumin(g/dl) 3.9 (0.2) 3.0 (0.6) 0.068 4.1 (0.5) 3.6 (0.5) 0.005
Aspartate Aminotransferase(IU/l) 54.2 (60.6) 43.3 (34.2) 0.893 23.8 (6.8) 33.5 (14.0) 0.068
Alanine Aminotransferase(IU/l) 47.0 (55.2) 34.1 (38.9) 0.500 20.8 (7.8) 22.6 (11.1) 0.480
Lactate Dehydrogenase(IU/l) 234.0 (32.2) 361.8 (92.8) 0.138 232.5 (43.0) 346.2 (158.2) 0.039
Alkaline Phosphatase(IU/l) 320.2 (169.8) 224.9 (67.2) 0.144 238.2 (82.4) 268.5 (103.1) 0.221
γ-glutamyltransferase(IU/l) 42.4 (32.7) 179.1 (413.2) 0.419 38.1 (37.5) 42.8 (44.2) 0.142
Creatinine(mg/dl) 0.7 (0.1) 0.7 (0.2) 0.419 0.7 (0.1) 0.7 (0.1) 0.422
Blood Urea Nitrogen(mg/dl) 13.1 (2.5) 15.1 (5.2) 0.715 14.5 (2.7) 18.1 (4.3) 0.039
C-reactive protein(mg/dl) 0.8 (0.5) 12.0 (8.6) 0.080 3.8 (3.7) 7.3 (9.0) 0.311
KL-6(U/ml) 1364.1 (2423.4) 1565.4 (2498.4) 0.025 837.5 (936.0) 1173.8 (898.0) 0.017
Surfactant Protein-D(ng/ml) 136.8 (125.6) 196.0 (114.4) 0.036 87.1 (60.4) 169.6 (167.8) 0.203
TIMP-1(pg/ml) 231906 (68528) 346576 (72337) 0.080 197816 (49624) 260193 (96764) 0.084
TIMP-2(pg/ml) 118406 (27648) 105669 (20160) 0.345 122762 (20616) 100361 (17629) 0.012
TIMP-3(pg/ml) 10668 (6632) 15759 (12498) 0.043 17743 (12977) 15609 (4998) 0.790
MMP-3(pg/ml) 752633 (495718) 513110 (247738) 0.214 919436 (751496) 490655 (348157) 0.030
MMP-9(pg/ml) 1769108 (1012232) 3358493 (1977141) 0.011 3159443 (1634403) 2502127 (1229009) 0.140
Osteopontin(pg/ml) 13588 (9212) 51660 (44658) 0.008 15256 (14407) 16430 (9537) 0.551
Eotaxin 2(pg/ml) 4854 (4321) 4320 (5943) 0.110 4267 (2079) 4160 (4408) 0.096
IL-1RA(pg/ml) 224 (463) 657 (559) 0.086 112 (190) 236 (352) 0.445
IL-2Rα(pg/ml) 3827 (2213) 8408 (4328) 0.011 3492 (2072) 6865 (7488) 0.064
IL-6(pg/ml) 156 (339) 710 (1157) 0.066 69 (115) 140 (222) 0.328
MMP-1(pg/ml) 35772 (19709) 73909 (39388) 0.011 91449 (103647) 76538 (67816) 0.397
MMP-8 (pg/ml) 14814 (12583) 51014 (40613) 0.008 32889 (16905) 47213 (62177) 0.826
MMP-3/MMP-1 23.67 (18.54) 10.29 (8.39) 0.028 21.00 (18.50) 18.02 (23.73) 0.221
AoDILD: Acute-onset diffuse interstitial lung disease. Average values of each group are shown. Standard deviations are shown in parenthesis. Differences were
tested by Wilcoxon signed-rank test.
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The characteristics of 23 collagen disease patients with
AoDILD are shown in Additional file 6: Table S5. There
were no significant differences between those who
died and those who survived. KL-6 and SP-D were
increased and red blood cell count, hemoglobin, and
hematocrit were decreased in the AoDILD state of
patients who died (n = 9, Table 4). Lactate dehydrogen-
ase, blood urea nitrogen and KL-6 were increased and
albumin decreased in the AoDILD state in patients who
survived (n = 14). TIMP-3, MMP-9, osteopontin, IL-
2Rα, MMP-1, and MMP-8 levels were significantly
increased in the AoDILD state in the deceased patients.The ratio of MMP-3 to MMP-1 was decreased in the
AoDILD state in the deceased patients (Table 4,
Figure 1C). On the other hand, the serum TIMP2 and
MMP-3 levels were decreased in the AoDILD state in
patients who survived. Thus, biomarker profiles were
different in patients with different outcomes.
Discussion
Many studies have reported on biomarker profiles in IPF
or ARDS patients [4-6]. The roles of MMPs and TIMPs in
IPF or ARDS have been reported [10-12]. Involvement of
other biomarkers in IPF or ARDS, including osteopontin
[13], eotaxin 2 (CCL24) [14], IL-1RA [15,16], IL- 2Rα [17],
Oka et al. BMC Immunology 2013, 14:9 Page 7 of 8
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reports novel biomarker profiles of AoDILD occurring in
collagen disease patients, though a few of these biomar-
kers have been analyzed previously in such patients with
chronic CVD-ILD [20,21]. Administration of the cytokines
found to be decreased, or blocking cytokines found to be
increased with antibodies or inhibitors could represent
new therapeutic approaches for AoDILD in collagen dis-
ease patients [22].
We also propose that serum biomarker patterns could
represent prognostic markers for AoDILD in collagen
diseases. Several studies reported that the expression of
MMP-1 and MMP-3 by fibroblasts and chondrocytes
was correlated [12,23]. This was measured as the ratio of
MMP-3 to MMP-1 and was maintained in the sera of
patients who survived, but not in those who died
(Table 4, Figure 1C). Similarly, different biomarker pro-
files were seen in deceased and surviving patients. These
biomarkers were up-regulated in the sera of the patients
with AoDILD who died (TIMP-3, MMP-9, osteopontin, IL-
2Rα, MMP-1, and MMP-8, Figure 1C) or down-regulated
in the sera of the patients with AoDILD who survived
(TIMP2 and MMP-3). These biomarker molecules might
accelerate the progress of AoDILD and could be targets
blocked with antibodies or inhibitors for the treatment.
Since there were no oppositely regulated biomarker mole-
cules, we could not find any molecules that might prevent
the progress of AoDILD. Role of other molecules in the
pathological state of AoDILD, such as TIMP-1, eotaxin 2,
IL-1RA, or IL-6 could not be estimated in this study. Thus,
the MMP-3 to MMP-1 ratio, and levels of TIMP-3, MMP-
9, and osteopontin could be prognostic markers for
AoDILD in collagen diseases.
The serum osteopontin (P = 0.0233, Mann-Whitney U
test), IL-1RA (P = 0.0350), and IL-6 (P = 0.0320) levels
were higher in patients who died in the AoDILD state,
compared with those who survived (Table 4). The serum
MMP-9 (P = 0.0376, Mann-Whitney U test) and MMP-8
(P = 0.0167) levels were higher in patients who survived in
the stable state, compared with those who died (Table 4).
These data suggest that some biomarkers could represent
prognosis of the patients with AoDILD, without compari-
son of the paired serum levels between stable and AoDILD
states.
The ratio of MMP-3 to MMP-1 was maintained
in the sera of AE-ILD patients (Table 3, Figure 1B).
However, the correlation was no longer present in DI-ILD
patients (Table 3). In addition, serum profiles of
eotaxin 2 and MMP-3 were completely different in
patients with AE-ILD and DI-ILD. The serum IL-
2Rα, (P = 0.0406, Mann-Whitney U test) and MMP-1
(P = 0.0140) levels were higher in patients with DI-ILD in
the AoDILD state, compared with those with AE-ILD
(Table 3). The ratio of MMP-3 to MMP-1 was lower inpatients with DI-ILD in the AoDILD state, compared with
those with AE-ILD (P = 0.0068, Table 3). The serum
MMP-1 (P = 0.0016, Mann-Whitney U test) level was
higher in patients with DI-ILD in the stable state, com-
pared with those with AE-ILD (Table 3). Thus, our find-
ings suggest the possibility of different pathogenesis of
AE-ILD and DI-ILD. Because of the limited sample size of
this study, the expression pattern of these biomarkers
needs to be confirmed in future studies.
Conclusions
To our knowledge, this is the first report of biomarker
profiling in AoDILD occurring in collagen disease
patients. Our findings support the role of serum bio-
marker profiles as prognosis markers for AoDILD.
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